Skip to main content

Table 1 Demographics of patients treated at Stanford Cancer Institute and TCGA

From: A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis

Characteristic Stanford patients (n = 152) TCGA (n = 206)
Age at diagnosis 54.5 (15–90) 60 (20–90)
Sex
 Male 74 (48.7%) 94 (46%)
 Female 78 (51.3%) 112 (54%)
Race or ethnic group
 Caucasian 104 (68%) N/A
 Hispanic 22 (14%)  
 Asian 22 (14%)  
 Other 4 (3%)  
Tumor histology
 Leiomyosarcoma 25 80
 Undifferentiated pleomorphic sarcoma 23 44
 Sarcoma (NOS) 14  
 Myxofibrosarcoma 13 17
 Liposarcoma 13 50
 Malignant peripheral nerve sheath tumor 9 5
 Synovial sarcoma 7 10
 Osteosarcoma 5  
 Angiosarcoma 5  
 Rhabdomyosarcoma 3  
 Ewing’s sarcoma 3  
 Chondrosarcoma 3  
 Malignant phyllodes tumor 3  
Local or metastatic
 Local 106 (70%) 89 (43%)
 Locally advanced 8 (5%)  
 Metastatic 38 (25%) 46 (22%)
 Unknown   71 (34%)
Site
 Extremity 46 (30%) 62 (30%)
 Pelvic 31 (20%) 33 (16%)
 Trunk 15 (10%) 9 (4%)
 Retroperitoneum 21 (14%) 87 (42%)
 Spine 9 (6%) 0
 Breast 6 (4%) 0
 Lungs 4 (3%) 2 (1%)
 Other 10 (7%) 13 (6%)
Size (cm) 11.4 (2–42) 12.7 (1.2–39.5)
FNCLCC grade
 I 7 (5%) 14 (7%)
 II 23 (15%) 112 (54%)
 III 37 (24%) 80 (39%)
 N/A 85 (56%)  
Adjuvant chemotherapy
 Yes 48 (41%) 47 (23%)
 No 70 (59%) 150 (73%)
 N/A   9 (4%)
Adjuvant radiotherapy
 Yes 78 (66%) 58 (28%)
 No 37 (31%) 139 (67%)
 N/A   9 (4%)